Nektar Therapeutics (NKTR) Gross Profit (2010 - 2026)

Nektar Therapeutics' Gross Profit history runs 17 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• In Q1 2026, Gross Profit rose 146.46% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $37.6 million (up 32.45% YoY), while the FY2025 annual figure was $55.2 million, down 2.04% from the prior year.
• Gross Profit for Q1 2026 stood at $3.2 million, down from $21.8 million in the prior quarter.
• The five-year high for Gross Profit was $21.8 million in Q4 2025, with the low at -$6.8 million in Q1 2025.
• The 5-year median for Gross Profit is $13.1 million (2024), against an average of $11.8 million.
• The sharpest annual moves came in 2025 and 2026: Gross Profit slumped 165.17% in 2025, then soared 146.46% in 2026.
• Nektar Therapeutics' Gross Profit stood at $15.8 million in 2022, then declined by 15.63% to $13.3 million in 2023, then declined by 26.16% to $9.8 million in 2024, then surged by 121.68% to $21.8 million in 2025, then slumped by 85.51% to $3.2 million in 2026.
• Business Quant data shows NKTR's Gross Profit at $3.2 million in Q1 2026, $21.8 million in Q4 2025, and $1.5 million in Q3 2025.